Anthem Biosciences

What Anthem Biosciences does

Anthem Biosciences is an integrated Contract Research, Development and Manufacturing Organization (CRDMO) headquartered in Bangalore, India, founded in 2006 by Ajay Bhardwaj, a former Biocon executive. The company provides end-to-end drug discovery, development, and commercial manufacturing services spanning both small molecules (synthetic chemistry, HPAPI, peptides, lipids, oligonucleotides, ADCs) and large molecules (recombinant proteins, monoclonal antibodies, enzymes using microbial and mammalian platforms). Underpinning the platform is a New Age Chemistry capability set covering Biocatalysis, Flow Chemistry, Green Chemistry, Micellar Chemistry, and Pincer Catalysis, supported by an AAALAC-accredited 30,000 sq. ft. vivarium for discovery biology and GLP toxicology studies. Regulatory credentials include multiple successful USFDA inspections (Unit I in 2013, 2017, 2019, 2025; Unit II in 2023, 2024), plus ANVISA, PMDA, and TGA certifications.

The company generates approximately 84% of revenue from CRDMO services delivered under multi-year, project-based contracts with global pharmaceutical companies and emerging biotech firms, with the balance coming from a Specialty Ingredients product line (fermentation products, probiotics, enzymes, biosimilars, nutritional actives) and an Animal Nutrition product range (probiotics, NSP enzymes, protease blends, phytase). Pricing is custom-negotiated per project rather than published; long-term contracts with milestone-based payments are typical. Manufacturing spans four units in the Bangalore area: Unit I (Bommasandra, 5 acres, 24 KL reactor capacity), Unit II (Harohalli, 15 acres, 376 KL reactor capacity with 140 KL fermentation), Unit III NeoAnthem (Harohalli, 8 acres, 25 KL custom synthesis and 40 KL fermentation including peptides and HPAPI), and Unit IV (Harohalli, 30 acres, under construction). Distribution is direct enterprise field sales targeting pharmaceutical and biotech buyers globally.

Anthem completed its IPO on BSE (544449) and NSE (ANTHEM) in July 2025, raising approximately $410 million at a market capitalization of roughly $4.5 billion. For Q4 FY26, revenue from operations reached Rs 611 crore (up 26.50% YoY) with consolidated net profit of Rs 190 crore (up 128.92% YoY). Promoter Aruna Ganesh holds approximately 71.63% post a June 2026 block-deal divestment, the company has ~40% employee ownership via ESOPs, and True North exited via a March 2026 open-market sale. Management's stated objective is to roughly quintuple revenue toward $1 billion through the Rs 1,200 crore Harohalli greenfield Phase I expansion and ongoing Unit IV construction.

Name

Anthem Biosciences

Legal name

Anthem Biosciences Pvt. Ltd.

Website

https://anthembio.com

Company type

Public

Founded year

2006

Operating status

Ipo

Headcount range

1,001–5,000 employees

Short description

Anthem Biosciences is a Bangalore-based, publicly listed CRDMO offering integrated drug discovery, development, and commercial manufacturing across small molecules, large molecules, peptides, HPAPI, ADCs, and oligonucleotides for global pharmaceutical and biotech clients. Founded 2006; listed on NSE/BSE since July 2025.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing and Development Services

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro industry

PRIMARYHLAGAHAL

GMP Scale-Up, Tech Transfer & Process Validation (PPQ)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

SECONDARYHLAGAAAB

Preclinical CROs (Discovery/Pharmacology/DMPK)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Research Organizations (CRO)

SECONDARYHLAGAHAM

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

SECONDARYHLAGAAAC

Toxicology & Safety Assessment CROs (GLP)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Research Organizations (CRO)

SECONDARYHLAGAAAA

Clinical CROs (Phase I–IV)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Research Organizations (CRO)

SECONDARYHLAGAAAD

Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Research Organizations (CRO)

Keywords

• Contract research services
• Drug development manufacturing
• Small molecule manufacturing
• Biologics contract manufacturing
• Peptide manufacturing services

Headquarters

HQ city

Bangalore

HQ country

India

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. CRDMO Services (Contract Research, Development & Manufacturing): Provides integrated services across drug discovery, development, and commercial manufacturing for pharmaceutical and biotech clients. Revenue is generated through project-based contracts, typically long-term agreements with milestone-based payments. The CRDMO segment accounts for approximately 84% of total revenue.
2. Specialty Ingredients: Manufactures and supplies specialty ingredients including fermentation products, probiotics, functional enzymes, peptides, biosimilars, nutritional actives, vitamin analogues, APIs, and biotransformation enzymes to pharmaceutical and nutrition companies.
3. Animal Nutrition Products: Biotech-backed solutions for animal health including probiotics, enzymes (NSP enzymes, proteases, phytase), and specialty products for poultry, ruminants, aquaculture, and swine. Revenue generated through product sales to animal nutrition companies.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Anthem Biosciences is an integrated Contract Research, Development and Manufacturing Organization (CRDMO) providing end-to-end pharmaceutical services from drug discovery through clinical and commercial manufacturing. The company serves pharmaceutical and biotechnology innovators with capabilities spanning both small molecules (synthetic and medicinal chemistry, HPAPI, peptides, lipids, ADCs, oligonucleotides) and large molecules (recombinant proteins, monoclonal antibodies, enzymes using microbial and mammalian platforms). Services are delivered through USFDA-, ANVISA-, PMDA-, and TGA-certified manufacturing facilities in Bangalore, India, supported by advanced New Age Chemistry platforms and an AAALAC-accredited vivarium for discovery biology and preclinical studies.

Product overview

Anthem Biosciences is a fully integrated Contract Research, Development and Manufacturing Organization (CRDMO) operating as a single connected platform across the pharmaceutical product lifecycle. The company provides end-to-end services spanning drug discovery, development, and commercial manufacturing for both small molecules and large molecules (biologics). The core CRDMO services are organized around two primary pillars: Small Molecules (encompassing Discovery, Synthetic & Medicinal Chemistry, Discovery Biology, Analytical Services, QA/QC, and GMP Manufacturing) and Large Molecules (encompassing Discovery & Pre-clinical, Protein Sciences, Antibody Generation, Biologics Development, and GMP Manufacturing). Supporting these are specialized technology platforms including HPAPI, Peptides, Lipids, ADCs, Oligonucleotides, and a New Age Chemistry Platform (Biocatalysis, Flow Chemistry, Green Chemistry, Micellar Chemistry, Pincer Catalysis). The company also operates a Specialty Ingredients division producing fermentation products, probiotics, functional enzymes, biosimilars, nutritional actives, vitamin analogues, APIs, and biotransformation enzymes, as well as an Animal Nutrition product line serving livestock markets. Manufacturing infrastructure includes three units: Unit I (Bommasandra, established 2007), Unit II (Harohalli, established 2016), and Unit III (Neo Anthem, established 2024), with Unit IV under construction.

Differentiator

Problem solved

Functional benefit

Brands

• NeoAnthem Lifesciences: Subsidiary focused on peptides, high-potency manufacturing, probiotics, enzymes, sterile drug product manufacturing, and biosimilar drug substance production.

Products and services

• Small Molecules CRDMO Services End-to-end contract research, development, and manufacturing services for small molecule drug substances, ranging from medicinal chemistry leads to complex high-potent APIs. Includes integrated drug discovery, synthetic and medicinal chemistry, discovery biology, analytical services, QA/QC, and GMP manufacturing for pharmaceutical and biotech clients.
• Large Molecules CRDMO Services Comprehensive contract development of biologics including recombinant proteins, monoclonal antibodies, and enzymes using advanced microbial and mammalian platforms, spanning discovery and pre-clinical through clinical and commercial GMP manufacturing for pharmaceutical and biotech clients.
• HPAPI (High-Potency APIs) Manufacturing Contract manufacturing of highly potent active pharmaceutical ingredients requiring specialized handling and containment facilities for compounds with low occupational exposure limits. Targeted at oncology and other high-potency therapeutic categories.
• Peptide Manufacturing Contract development and manufacturing of peptide-based therapeutics, including custom peptide synthesis and large-scale commercial production. Includes dedicated 16 KL peptide manufacturing capacity at NeoAnthem Lifesciences subsidiary.
• Lipid Manufacturing Contract development and manufacturing services for lipid-based pharmaceutical ingredients and delivery systems, including lipid nanoparticles for nucleic acid therapeutics.
• Antibody-Drug Conjugates (ADCs) Manufacturing Contract development and manufacturing of antibody-drug conjugates combining antibodies with cytotoxic drug payloads for targeted cancer therapy, including specialized conjugation technology.
• Oligonucleotide Manufacturing Contract development and manufacturing of oligonucleotide-based therapeutics including antisense oligonucleotides and siRNA constructs.
• New Age Chemistry Platform Advanced chemistry technologies offered to clients including Biocatalysis, Flow Chemistry, Green Chemistry, Micellar Chemistry, and Pincer Catalysis for sustainable and efficient manufacturing process development of small molecules.
• Specialty Ingredients Portfolio of fermentation products, probiotics, functional enzymes, biosimilars, nutritional actives, vitamin analogues, APIs, and biotransformation enzymes for pharmaceutical and nutritional applications.
• Animal Nutrition Products Biotech-backed product line for livestock including probiotics, NSP enzymes, protease blends, phytase preparations, and specialty products for Poultry, Ruminants, Aquaculture, and Swine. Specific products include ACILAC DS, ALBITON, ARROWNEXT PR 100 E, ARROWZYME, LYSOGUARD, NUTRIVET PRO, and ZYME BOOSTER.

Quantifiable outcome

• 85% programs successfully scaled from development to manufacturing
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

One partnership is on record.

• Kfin Technologies LimitedminorOthers · 9 March 2026Registrar and Transfer Agent for Anthem Biosciences managing share registry, investor queries, and corporate actions. Located in Hyderabad.

Scale indicators14 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Syngene International: India-based integrated CRDMO offering discovery, development, and manufacturing services across small and large molecules for global pharma and biotech. Closest direct competitor with similar integrated model and customer base.
• Piramal Pharma Solutions: India-headquartered CDMO offering integrated drug substance and drug product solutions across small molecules, ADCs, and peptides. Directly comparable scope and global customer overlap with Anthem.
• Divi's Laboratories: India-based leading API and CDMO with strong custom synthesis and generics capabilities. Comparable in scale and India manufacturing footprint, with significant overlap in small molecule custom synthesis.
• Laurus Labs: India-headquartered pharmaceutical company with CDMO services for APIs, formulation, and biotech. Overlapping capabilities in small molecule manufacturing and emerging biologics.
• Sai Life Sciences: India-based CRDMO providing integrated drug discovery, development, and manufacturing services. Highly comparable business model targeting innovator pharma and biotech globally.
• Aragen Life Sciences: India-based CRDMO offering discovery, development, and manufacturing services for small and large molecules. Direct competitor in integrated CRDMO services to global pharma.

Emerging players

• Neuland Labs: India-based API and custom manufacturing company focused on small molecule APIs and peptides. Comparable manufacturing capabilities though smaller scale and less integrated than Anthem.

Broad incumbents

• Lonza: Global largest CDMO offering integrated small molecule, biologics, and cell therapy services. Sets the standard for scale, capabilities, and regulatory reach that Anthem competes against in global outsourcing decisions.
• WuXi AppTec (WuXi STA): Global integrated CRDMO with extensive small and large molecule capabilities. Major competitor for global pharma outsourcing, though increasing US policy scrutiny creates opportunity for Anthem.
• Catalent: Global CDMO specializing in biologics, cell and gene therapy, and oral drug delivery. Comparable in scale and modality breadth, now part of Novo Holdings, providing competitive benchmark for Anthem's biologics expansion.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/AnthemBio

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Anthem Biosciences